KR940008694A - 비인슐린 의존성 당뇨병 환자의 장기간 치료를 위한 l-카르니틴 및 아실 l-카르니틴을 함유한 의약 조성물 및 그 용도 - Google Patents

비인슐린 의존성 당뇨병 환자의 장기간 치료를 위한 l-카르니틴 및 아실 l-카르니틴을 함유한 의약 조성물 및 그 용도 Download PDF

Info

Publication number
KR940008694A
KR940008694A KR1019930020825A KR930020825A KR940008694A KR 940008694 A KR940008694 A KR 940008694A KR 1019930020825 A KR1019930020825 A KR 1019930020825A KR 930020825 A KR930020825 A KR 930020825A KR 940008694 A KR940008694 A KR 940008694A
Authority
KR
South Korea
Prior art keywords
carnitine
acyl
diabetic patients
insulin dependent
pharmacologically acceptable
Prior art date
Application number
KR1019930020825A
Other languages
English (en)
Other versions
KR0136558B1 (ko
Inventor
카바짜 클라우디오
Original Assignee
알도 파시
씨구마-토오 인더스트리에 파아마슈티체 리유니테 에스.피.에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알도 파시, 씨구마-토오 인더스트리에 파아마슈티체 리유니테 에스.피.에이 filed Critical 알도 파시
Publication of KR940008694A publication Critical patent/KR940008694A/ko
Application granted granted Critical
Publication of KR0136558B1 publication Critical patent/KR0136558B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S426/00—Food or edible material: processes, compositions, and products
    • Y10S426/801—Pediatric

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

비인슐린 의존성 당뇨병 환자의 주변 글루코오스 이용증대를 목적으로 그 치료를 위하여 L-카르니틴, 아실 L-카르니틴 및 약리학적으로 허용되는 이들의 염의 신규 치료용도를 제공한다.

Description

비인슐린 의존성 당뇨병 환자의 장기간 치료를 위한 L-카르니틴 및 아실 L-카르니틴을 함유한 의약 조성물 및 그 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (5)

  1. L-카르니틴 또는 탄소 원자수가 2~6인 직쇄상 혹은 측쇄달린 아실그룹을 가진 아실 L-카르니틴 또는 약리학적으로 허용되는 이들의 염을 활성 성분으로 함유하고 약리학적으로 허용되는 이들의 부형제들을 함유함을 특징으로 하는 비인슐린 의존성 당뇨병 환자의 주변 글루코오스 이용을 증대시키는 경구 또는 비경구 투여용 의약 조성물.
  2. 제1항에 있어서, 아실 L-카르니틴은 아세틸, 프로피오닐, 부티릴, 발레릴 및 이소발레릴 L-카르니틴인 조성물.
  3. L-카르니틴 또는 탄소 원자수가 2~6인 직쇄상 혹은 측쇄달인 알카노일 그룹을 가진 알카노일 L-카르니틴 또는 약리학적으로 허용되는 이들의 염의 주변 글루코오스 이용 증대에 필요한 투여량을 당뇨병 환자에게 경구 또는 비경구 투여하는 비인슐린 의존성 당뇨병 환자의 글루코오스 이용증대를 위한 치료방법.
  4. 제3항에 있어서. L-카르니틴을 체중 1㎏달 1일 20~50㎎ 또는 이와 균등량의 알카노일 L-카르니틴 혹은 약리학적으로 허용되는 이들의 염을 투여하는 치료방법.
  5. L-카르니틴 또는 탄소 원자수가 2~6인 직쇄상 또는 측쇄 달린 아실 그룹을 가진 아실 L-카르니틴 혹은 약리학적으로 허용되는 이들의 염의 비인슐린 의존성 당뇨병 환자의 주변 의존성 당뇨병 환자의 주변 글루코오스 이용 증대를 위한 의약 제조를 위한 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930020825A 1992-10-08 1993-10-08 비인슐린 의존성 당뇨병 환자의 장기간 치료를 위한 l - 카르니틴 및 아실 l - 카르니틴을 함유한 의약 조성물 및 그 용도 KR0136558B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITPM92A000731 1992-10-08
ITRM92A000731 1992-10-08
ITRM920731A IT1263004B (it) 1992-10-08 1992-10-08 Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.

Publications (2)

Publication Number Publication Date
KR940008694A true KR940008694A (ko) 1994-05-16
KR0136558B1 KR0136558B1 (ko) 1998-04-25

Family

ID=11401226

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930020825A KR0136558B1 (ko) 1992-10-08 1993-10-08 비인슐린 의존성 당뇨병 환자의 장기간 치료를 위한 l - 카르니틴 및 아실 l - 카르니틴을 함유한 의약 조성물 및 그 용도

Country Status (6)

Country Link
US (1) US5430065A (ko)
EP (1) EP0591857A1 (ko)
JP (1) JPH06192079A (ko)
KR (1) KR0136558B1 (ko)
CA (1) CA2107737A1 (ko)
IT (1) IT1263004B (ko)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19530298C2 (de) * 1995-08-17 1999-07-22 Woerwag Pharma Gmbh Verwendung von Orotsäure zur Prävention und Therapie des metabolischen Syndroms
IT1276225B1 (it) * 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
IT1276253B1 (it) 1995-12-15 1997-10-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o alcanoil l-carnitine per la prevenzione ed il trattamento di stati morbosi
IT1277953B1 (it) * 1995-12-21 1997-11-12 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
US5872008A (en) * 1996-02-09 1999-02-16 Bair; Glenn O. Methods for diagnosing pre-menstrual syndrome
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
US5863940A (en) 1997-12-01 1999-01-26 Sigma-Tau Healthscience S.P.A. Medicament and therapeutical method for treating idiopathic asthenozoospermia
US6090848A (en) * 1997-12-01 2000-07-18 Sigma-Tau Healthscience S.P.A. Compositions and methods for increasing the concentration and/or motility of spermatozoa in humans
SI0951909T2 (sl) 1998-03-19 2010-11-30 Sigma Tau Ind Farmaceuti Kombinirana zmes ki vsebuje L karnitin ali alkanoil L karnitin glikozaminoglikan in ali njegov sestavni del
IT1299266B1 (it) * 1998-05-15 2000-02-29 Sigma Tau Ind Farmaceuti Inibitori reversibili della carnitina palmitoil trasferasi
ITRM20010294A1 (it) * 2001-05-29 2002-11-29 Sigma Tau Ind Farmaceuti Uso della acetil l-carnetina in associazione con la biotina per il trattamento di pazienti affetti da diabete mellito di tipo ii insulino re
DE10331202A1 (de) 2003-07-10 2005-03-31 S.K. Enterprise Gmbh Verwendung von Molkenpermeat zur Behandlung des Metabolischen Syndroms
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
ITRM20040327A1 (it) * 2004-07-01 2004-10-01 Sigma Tau Ind Farmaceuti Uso della acetil l-carnitina per la preparazione di un medicamento per il trattamento del dolore neuropatico in pazienti diabetici.
US20080161604A1 (en) * 2005-04-26 2008-07-03 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Acetyl L-Carnitine For Preventing Painful Peripheral Diabetic Neuropathy
DE102006036285A1 (de) 2006-08-03 2008-02-07 "S.U.K." Beteiligungs Gmbh Fraktionen aus Molkepermeat und deren Verwendung zur Prävention und Therapie des Typ-2 Diabetes und des Metabolischen Syndroms
JP5697337B2 (ja) * 2007-02-27 2015-04-08 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニＳｉｇｍａ−Ｔａｕ Ｉｎｄｕｓｔｒｉｅ Ｆａｒｍａｃｅｕｔｉｃｈｅ Ｒｉｕｎｉｔｅ Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ ２型糖尿病の処置に有用な組成物
EP2136798B1 (en) * 2007-03-21 2015-07-29 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Composition useful for the prevention of type 2 diabetes and its complications in pre-diabetic patients with insulin resistance
EP2162127A1 (en) * 2007-05-24 2010-03-17 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Composition useful for the prevention of adverse effect due to the use of ppar-gamma agonists
GB201304112D0 (en) * 2013-03-07 2013-04-24 Univ Nottingham Modulation of energy expenditure
AU2018258250A1 (en) 2017-04-25 2019-12-12 Almeda Labs Llc Amino acid formulations for pancreatic viability

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU518617B2 (en) * 1977-04-29 1981-10-08 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Therapeutic application of acetyl-d, 1-carnitine
IT1206954B (it) * 1979-02-12 1989-05-17 Sigma Tau Ind Farmaceuti Agenti terapeutici a base di un acil derivato della carnitina per la cura di vasculopatie periferiche
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
IT1120033B (it) * 1979-10-05 1986-03-19 Sigma Tau Ind Farmaceuti Composizione farmaceutica comprendente-carnitina adatta per l'alimentazione parenterale
IT1143214B (it) * 1981-07-09 1986-10-22 Sigma Tau Ind Farmaceuti Acil derivato della carnitina quale immunomodulatore
IT1142934B (it) * 1981-11-06 1986-10-15 Sigma Tau Ind Farmaceuti Uso della carnitina e delle acilcarnitine inferiori nel trattamento terapeutico della patologia delle vene
IT1150396B (it) * 1982-12-09 1986-12-10 Sigma Tau Ind Farmaceuti Impiego di alcanoil l-carnitine per il trattamento terapeutico di miopa tie e distrofie muscolari
IT1181682B (it) * 1985-06-11 1987-09-30 Sigma Tau Ind Farmaceuti Impiego di alcanoil l-carnitine per il trattamento terapeutico del parkinsonismo idiopatico o indotto
IT1184655B (it) * 1985-10-14 1987-10-28 Sigma Tau Ind Farmaceuti Imiego di acetil l-carnitina nel trattamento terapeutico degli stati di shock
IT1196564B (it) * 1986-08-04 1988-11-16 Sigma Tau Ind Farmaceuti Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche
US4921877A (en) * 1986-10-27 1990-05-01 Abbott Laboratories Liquid nutritional formula for glucose intolerance
US5070074A (en) * 1987-08-07 1991-12-03 Protor Co. Hypoglycemic and growth-promoting polypeptides isolated from bacitracin
IT1235153B (it) * 1988-11-15 1992-06-22 Sigma Tau Ind Farmaceuti Uso dell'acetil l-carnitina nel trattamento terapeutico della cataratta e composizioni farmaceutiche utili in tale trattamento
IT1224795B (it) * 1988-12-01 1990-10-24 Sigma Tau Ind Farmaceuti Uso dell'acetil d-carnitina nel trattamento terapeutico del glaucoma e composizioni farmaceutiche utili in tale trattamento
IT1224842B (it) * 1988-12-27 1990-10-24 Sigma Tau Ind Farmaceuti Uso di derivati della l-carnitina nel trattamento terapeutico delle alterazioni degenerative del sistema nervoso
IT1240799B (it) * 1990-03-15 1993-12-17 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche contenenti 3-metiltiopropionil l-carnitina ad attivita' sul sistema cardiovascolare.
IT1244636B (it) * 1991-01-04 1994-08-08 Sigma Tau Ind Farmaceuti Uso dell'acetil l-carnitina nel trattamento terapeutico del coma e composizioni farmaceutiche utili in tale trattamento.
FR2673812B1 (fr) * 1991-03-13 1994-04-01 Roussel Uclaf Nouvelles compositions destinees a etre utilisees en dietetique et en therapeutique et renfermant une combinaison particuliere de glucides et leurs applications.

Also Published As

Publication number Publication date
ITRM920731A0 (it) 1992-10-08
KR0136558B1 (ko) 1998-04-25
ITRM920731A1 (it) 1994-04-08
IT1263004B (it) 1996-07-23
CA2107737A1 (en) 1994-04-09
JPH06192079A (ja) 1994-07-12
US5430065A (en) 1995-07-04
EP0591857A1 (en) 1994-04-13

Similar Documents

Publication Publication Date Title
KR940008694A (ko) 비인슐린 의존성 당뇨병 환자의 장기간 치료를 위한 l-카르니틴 및 아실 l-카르니틴을 함유한 의약 조성물 및 그 용도
US4255449A (en) Method of treating abnormal lipoprote in ratios
KR920702216A (ko) 아세틸 d-카르니틴의 녹내장 치료에의 용도
CA2029596C (en) Medicaments containing r-a-lipoic acid
US4268524A (en) Method of treating abnormal lipoprotein ratios with acylcarnitine
KR880002515A (ko) 흡수 및 작용이 빠른 설린다크 또는 나트륨 설린다크와 염기의 혼합물
PT659408E (pt) Utilizacao de acido r-(alfa-lipoico, acido r(-) - di-hidrolipoico e metabolitos para o tratamento da diabetes mellitus bem como das doencas secundarias
KR920000324A (ko) 필수 지방산 처리법
ES2052717T3 (es) Uso de derivados de indolona para la preparacion de medicamentos para el tratamiento de la enfermedad de parkinson.
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
NZ209843A (en) Transdermal delivery system for administration of nitroglycerin
KR950703953A (ko) 2-아미노-6-n-프로필아미노-4, 5, 6, 7-테트라하이드로벤조티아졸(프라미펙솔)의 항우울제로서의 용도(Use of 2-amino-6-n-propylamino-4, 5, 6, 7-tetrahydrobenzothiazole (pramipexol)as an antidepressant drug)
KR970025615A (ko) 암 전이 억제제
KR950007848A (ko) (S)-(-)-α-에틸-2-옥소-1-피롤리딘아세트아미드를 사용한 불안치료방법
Turner β-Adrenergic receptor blocking drugs in hyperthyroidism
SE8103003L (sv) Terapeutisk forfarande for behandling av diabetes och farmaceutisk komposition for genomforande av forfarandet
US4663352A (en) Use of some alkanoyl L-carnitines for the therapeutical treatment of idiopathic and induced Parkinsonism
KR920000326A (ko) 사람에 있어서 몰핀 및 동족체의 진통 효과에 대한 내성 발생을 방지하기 위한 gm₁모노시알로강글리오사이드 및 이의 내부 에스테르 유도체의 용도
KR920019350A (ko) 자기면역질환요법을 위한 약제조성물
WO1993017691A3 (en) Pharmaceutical compositions containing monosialoganglioside gm1 or a derivative thereof suitable for the treatment of parkinson's disease
KR19980070878A (ko) 새로운 진통제 조성물
CH642847A5 (en) Pharmaceutical composition for the treatment of heart disease
US4556663A (en) Benzoylecgonine, benzoylnorecgonine and ecgonine as active agents for the treatment of rheumatoid arthritis and osteoarthritis
KR930007442A (ko) L-카르니틴 및 아실 l-카르니틴의 원발성 정충무력 과소증 치료에의 용도
IE51711B1 (en) Carnitine derivatives

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20001228

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee